Links to Exploration step
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">History of Hypertension and the Effects of Eplerenone in Patients with Acute Myocardial Infarction Complicated by Systolic Heart Failure</title><author><name sortKey="Pitt, Bertram" sort="Pitt, Bertram" uniqKey="Pitt B" first="Bertram" last="Pitt">Bertram Pitt</name></author><author><name sortKey="Ahmed, Ali" sort="Ahmed, Ali" uniqKey="Ahmed A" first="Ali" last="Ahmed">Ali Ahmed</name></author><author><name sortKey="Love, Thomas E" sort="Love, Thomas E" uniqKey="Love T" first="Thomas E." last="Love">Thomas E. Love</name></author><author><name sortKey="Krum, Henry" sort="Krum, Henry" uniqKey="Krum H" first="Henry" last="Krum">Henry Krum</name></author><author><name sortKey="Nicolau, Jose" sort="Nicolau, Jose" uniqKey="Nicolau J" first="Jose" last="Nicolau">Jose Nicolau</name></author><author><name sortKey="Silva Cardoso, Jose" sort="Silva Cardoso, Jose" uniqKey="Silva Cardoso J" first="José" last="Silva Cardoso">José Silva Cardoso</name></author><author><name sortKey="Parkhomenko, Alexander" sort="Parkhomenko, Alexander" uniqKey="Parkhomenko A" first="Alexander" last="Parkhomenko">Alexander Parkhomenko</name></author><author><name sortKey="Aschermann, Michael" sort="Aschermann, Michael" uniqKey="Aschermann M" first="Michael" last="Aschermann">Michael Aschermann</name></author><author><name sortKey="Corbalan, Ramon" sort="Corbalan, Ramon" uniqKey="Corbalan R" first="Ramon" last="Corbalán">Ramon Corbalán</name></author><author><name sortKey="Solomon, Henry" sort="Solomon, Henry" uniqKey="Solomon H" first="Henry" last="Solomon">Henry Solomon</name></author><author><name sortKey="Shi, Harry" sort="Shi, Harry" uniqKey="Shi H" first="Harry" last="Shi">Harry Shi</name></author><author><name sortKey="Zannad, Faiez" sort="Zannad, Faiez" uniqKey="Zannad F" first="Faiez" last="Zannad">Faiez Zannad</name></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">18559720</idno><idno type="pmc">3782417</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3782417</idno><idno type="RBID">PMC:3782417</idno><idno type="doi">10.1161/HYPERTENSIONAHA.107.109314</idno><date when="2008">2008</date><idno type="wicri:Area/Pmc/Corpus">001F82</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">001F82</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">History of Hypertension and the Effects of Eplerenone in Patients with Acute Myocardial Infarction Complicated by Systolic Heart Failure</title><author><name sortKey="Pitt, Bertram" sort="Pitt, Bertram" uniqKey="Pitt B" first="Bertram" last="Pitt">Bertram Pitt</name></author><author><name sortKey="Ahmed, Ali" sort="Ahmed, Ali" uniqKey="Ahmed A" first="Ali" last="Ahmed">Ali Ahmed</name></author><author><name sortKey="Love, Thomas E" sort="Love, Thomas E" uniqKey="Love T" first="Thomas E." last="Love">Thomas E. Love</name></author><author><name sortKey="Krum, Henry" sort="Krum, Henry" uniqKey="Krum H" first="Henry" last="Krum">Henry Krum</name></author><author><name sortKey="Nicolau, Jose" sort="Nicolau, Jose" uniqKey="Nicolau J" first="Jose" last="Nicolau">Jose Nicolau</name></author><author><name sortKey="Silva Cardoso, Jose" sort="Silva Cardoso, Jose" uniqKey="Silva Cardoso J" first="José" last="Silva Cardoso">José Silva Cardoso</name></author><author><name sortKey="Parkhomenko, Alexander" sort="Parkhomenko, Alexander" uniqKey="Parkhomenko A" first="Alexander" last="Parkhomenko">Alexander Parkhomenko</name></author><author><name sortKey="Aschermann, Michael" sort="Aschermann, Michael" uniqKey="Aschermann M" first="Michael" last="Aschermann">Michael Aschermann</name></author><author><name sortKey="Corbalan, Ramon" sort="Corbalan, Ramon" uniqKey="Corbalan R" first="Ramon" last="Corbalán">Ramon Corbalán</name></author><author><name sortKey="Solomon, Henry" sort="Solomon, Henry" uniqKey="Solomon H" first="Henry" last="Solomon">Henry Solomon</name></author><author><name sortKey="Shi, Harry" sort="Shi, Harry" uniqKey="Shi H" first="Harry" last="Shi">Harry Shi</name></author><author><name sortKey="Zannad, Faiez" sort="Zannad, Faiez" uniqKey="Zannad F" first="Faiez" last="Zannad">Faiez Zannad</name></author></analytic><series><title level="j">Hypertension</title><idno type="ISSN">0194-911X</idno><idno type="eISSN">1524-4563</idno><imprint><date when="2008">2008</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p id="P1">In the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (n=6632), eplerenone-associated reduction in all-cause mortality was significantly greater in those with a history of hypertension (Hx-HTN). There were 4007 patients with Hx-HTN (eplerenone: n=1983) and 2625 patients without Hx-HTN (eplerenone: n=1336). Propensity scores for eplerenone use, separately calculated for patients with and without Hx-HTN, were used to assemble matched cohorts of 1838 and 1176 pairs of patients. In patients with Hx-HTN, all-cause mortality occurred in 18% of patients treated with placebo (rate, 1430/10 000 person-years) and 14% of patients treated with eplerenone (rate, 1058/10 000 person-years) during 2350 and 2457 years of follow-up, respectively (hazard ratio [HR]: 0.71; 95% CI: 0.59 to 0.85; P<0.0001). Composite end point of cardiovascular hospitalization or cardiovascular mortality occurred in 33% of placebo-treated patients (3029/10 000 person-years) and 28% of eplerenone-treated patients (2438/10 000 person-years) with Hx-HTN (HR: 0.82; 95% CI: 0.72 to 0.94; P=0.003). In patients without Hx-HTN, eplerenone reduced heart failure hospitalization (HR: 0.73; 95% CI: 0.55 to 0.97; P=0.028) but had no effect on mortality (HR: 0.91; 95% CI: 0.72 to 1.15; P=0.435) or on the composite end point (HR: 0.91; 95% CI: 0.76 to 1.10; P=0.331). Eplerenone should, therefore, be prescribed to all of the post–acute myocardial infarction patients with reduced left ventricular ejection fraction and heart failure regardless of Hx-HTN.</p></div></front></TEI><pmc article-type="research-article"><pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
<pmc-dir>properties manuscript</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-journal-id">7906255</journal-id><journal-id journal-id-type="pubmed-jr-id">4217</journal-id><journal-id journal-id-type="nlm-ta">Hypertension</journal-id><journal-id journal-id-type="iso-abbrev">Hypertension</journal-id><journal-title-group><journal-title>Hypertension</journal-title></journal-title-group><issn pub-type="ppub">0194-911X</issn><issn pub-type="epub">1524-4563</issn></journal-meta><article-meta><article-id pub-id-type="pmid">18559720</article-id><article-id pub-id-type="pmc">3782417</article-id><article-id pub-id-type="doi">10.1161/HYPERTENSIONAHA.107.109314</article-id><article-id pub-id-type="manuscript">NIHMS215965</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>History of Hypertension and the Effects of Eplerenone in Patients with Acute Myocardial Infarction Complicated by Systolic Heart Failure</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Pitt</surname><given-names>Bertram</given-names></name></contrib><contrib contrib-type="author"><name><surname>Ahmed</surname><given-names>Ali</given-names></name></contrib><contrib contrib-type="author"><name><surname>Love</surname><given-names>Thomas E.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Krum</surname><given-names>Henry</given-names></name></contrib><contrib contrib-type="author"><name><surname>Nicolau</surname><given-names>Jose</given-names></name></contrib><contrib contrib-type="author"><name><surname>Silva Cardoso</surname><given-names>José</given-names></name></contrib><contrib contrib-type="author"><name><surname>Parkhomenko</surname><given-names>Alexander</given-names></name></contrib><contrib contrib-type="author"><name><surname>Aschermann</surname><given-names>Michael</given-names></name></contrib><contrib contrib-type="author"><name><surname>Corbalán</surname><given-names>Ramon</given-names></name></contrib><contrib contrib-type="author"><name><surname>Solomon</surname><given-names>Henry</given-names></name></contrib><contrib contrib-type="author"><name><surname>Shi</surname><given-names>Harry</given-names></name></contrib><contrib contrib-type="author"><name><surname>Zannad</surname><given-names>Faiez</given-names></name></contrib><aff id="A1">University of Michigan Health System (B.P.), Ann Arbor, MI, USA; School of Medicine (A.A.), University of Alabama at Birmingham, and VA Medical Center, Birmingham, AL, USA; School of Medicine, Case Western Reserve University, Cleveland, OH, USA (T.E.L.); Department of Epidemiology and Preventive Medicine (H.K.), Monash University, Prahan, Australia; Heart Institute (InCOR) (J.N.), University of São Paulo Medical School, São Paulo, Brazil; Departamento de Engenharia Electrotécnica e de Computadores (J.S.C.), Faculdade de Engenharia, Universidade do Porto, Portugal; Emergency Cardiology Department (A.P.), National Institute of Cardiology, Kiev, Ukraine; Interni Klinika (M.A.), Cardiovascular Center, Prague, Czech Republic; Departamento de Enfermedades Cardiovasculares, Hospital Clínico y Facultad de Medicina (R.C.), Pontifica Universidad Catolica de Chile, Santiago, Chile; Pfizer Inc (H.S., H.S.), New York, NY, USA; Clinical Investigation Center (FZ), INSERM-CHU de Nancy Hopital Jeanne d'Arc, Dommartinles Toul, France</aff></contrib-group><author-notes><corresp id="cor1">Bertram Pitt, MD, University of Michigan, 1500 E Medical Center Drive, 3910 Taubman Center, Ann Arbor, MI 48109-0366, 734-936-5260 (phone), 734-936-5256 (fax), <email>bpitt@med.umich.edu</email></corresp></author-notes><pub-date pub-type="nihms-submitted"><day>16</day><month>5</month><year>2013</year></pub-date><pub-date pub-type="epub"><day>16</day><month>6</month><year>2008</year></pub-date><pub-date pub-type="ppub"><month>8</month><year>2008</year></pub-date><pub-date pub-type="pmc-release"><day>24</day><month>9</month><year>2013</year></pub-date><volume>52</volume><issue>2</issue><fpage>271</fpage><lpage>278</lpage><abstract><p id="P1">In the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (n=6632), eplerenone-associated reduction in all-cause mortality was significantly greater in those with a history of hypertension (Hx-HTN). There were 4007 patients with Hx-HTN (eplerenone: n=1983) and 2625 patients without Hx-HTN (eplerenone: n=1336). Propensity scores for eplerenone use, separately calculated for patients with and without Hx-HTN, were used to assemble matched cohorts of 1838 and 1176 pairs of patients. In patients with Hx-HTN, all-cause mortality occurred in 18% of patients treated with placebo (rate, 1430/10 000 person-years) and 14% of patients treated with eplerenone (rate, 1058/10 000 person-years) during 2350 and 2457 years of follow-up, respectively (hazard ratio [HR]: 0.71; 95% CI: 0.59 to 0.85; P<0.0001). Composite end point of cardiovascular hospitalization or cardiovascular mortality occurred in 33% of placebo-treated patients (3029/10 000 person-years) and 28% of eplerenone-treated patients (2438/10 000 person-years) with Hx-HTN (HR: 0.82; 95% CI: 0.72 to 0.94; P=0.003). In patients without Hx-HTN, eplerenone reduced heart failure hospitalization (HR: 0.73; 95% CI: 0.55 to 0.97; P=0.028) but had no effect on mortality (HR: 0.91; 95% CI: 0.72 to 1.15; P=0.435) or on the composite end point (HR: 0.91; 95% CI: 0.76 to 1.10; P=0.331). Eplerenone should, therefore, be prescribed to all of the post–acute myocardial infarction patients with reduced left ventricular ejection fraction and heart failure regardless of Hx-HTN.</p></abstract><kwd-group><kwd>Eplerenone</kwd><kwd>hypertension</kwd><kwd>myocardial infarction</kwd><kwd>heart failure</kwd><kwd>morbidity</kwd><kwd>mortality</kwd></kwd-group><funding-group><award-group><funding-source country="United States">National Heart, Lung, and Blood Institute : NHLBI</funding-source><award-id>R01 HL085561-02 || HL</award-id></award-group></funding-group></article-meta></front></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001F82 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 001F82 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Pmc
|étape= Corpus
|type= RBID
|clé=
|texte=
}}
| This area was generated with Dilib version V0.6.33. |  |